Continuity and Change in the World Trade Organization: Pluralism Past, Present, and Future
American Journal of International Law · 2023-01 · 117 (1) · 1-47
DOI: 10.1017/ajil.2022.82 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of International Law, online erschienen am 25.01.2023. Verfasst von Robert Howse und 1 weiteren Autor:innen. Die Arbeit wurde bisher 34-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The World Trade Organization is at an important institutional crossroads, buffeted by critique and with its once-heralded dispute system in doubt. Despite some achievements at the 2022 MC12 Ministerial Conference, the WTO appears in crisis, without a strong institutional mandate. In this Article, we offer a vision for its future, rooted in a particular interpretation of its past. The WTO's legal architecture is characterized by a resilient pluralism, which seeks to preserve diversity of governance models and regulatory approaches, both economic and political, in the domestic orders of member states. Despite strong pressures to impose a neoliberal vision of the state-market relationship on states, this pluralism has persevered; it offers a response to the WTO's critics and a mandate for the WTO's future.
Zitieren
APA
Howse, R., & Langille, J. (2023). Continuity and Change in the World Trade Organization: Pluralism Past, Present, and Future. American Journal of International Law, 117(1), 1-47. https://doi.org/10.1017/ajil.2022.82
Vancouver
Howse R, Langille J. Continuity and Change in the World Trade Organization: Pluralism Past, Present, and Future. American Journal of International Law. 2023;117(1):1-47. doi:10.1017/ajil.2022.82
BibTeX
@article{Howse2023,
author = {Howse, Robert and Langille, Joanna},
title = {Continuity and Change in the World Trade Organization: Pluralism Past, Present, and Future},
journal = {American Journal of International Law},
year = {2023},
volume = {117},
number = {1},
pages = {1--47},
doi = {10.1017/ajil.2022.82}
}
EUVIMED